دورية أكاديمية
Antibiotic susceptibility of staphylococci isolates from patients with chronic conjunctivitis: including associated factors and clinical evaluation.
| العنوان: | Antibiotic susceptibility of staphylococci isolates from patients with chronic conjunctivitis: including associated factors and clinical evaluation. |
|---|---|
| المؤلفون: | Blanco C; Cornea and Refractive Surgery Unit, Vision Sana Research Group, Clínica de Oftalmología de Cali, Faculty of Medicine Pontificia Universidad Javeriana Cali , Cali, Colombia ., Núñez MX |
| المصدر: | Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics [J Ocul Pharmacol Ther] 2013 Nov; Vol. 29 (9), pp. 803-8. Date of Electronic Publication: 2013 Aug 14. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Association For Ocular Pharmacology And Therapeutics Country of Publication: United States NLM ID: 9511091 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-7732 (Electronic) Linking ISSN: 10807683 NLM ISO Abbreviation: J Ocul Pharmacol Ther Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: New York, NY : Association For Ocular Pharmacology And Therapeutics Original Publication: New York, NY : The Association, c1995- |
| مواضيع طبية MeSH: | Anti-Bacterial Agents/*pharmacology , Conjunctivitis, Bacterial/*microbiology , Staphylococcal Infections/*drug therapy , Staphylococcus/*drug effects, Adult ; Aza Compounds/pharmacology ; Chronic Disease ; Conjunctivitis, Bacterial/drug therapy ; Drug Resistance, Bacterial ; Fluoroquinolones ; Follow-Up Studies ; Humans ; Microbial Sensitivity Tests ; Middle Aged ; Moxifloxacin ; Quinolines/pharmacology ; Staphylococcal Infections/microbiology ; Staphylococcus/isolation & purification ; Staphylococcus aureus/drug effects ; Staphylococcus aureus/isolation & purification ; Staphylococcus epidermidis/drug effects ; Staphylococcus epidermidis/isolation & purification ; Treatment Outcome ; Vancomycin/pharmacology |
| مستخلص: | Purpose: To determine species of staphylococci in chronic conjunctivitis, their antibiotic susceptibility pattern, patient treatments, clinical course, and clinical conditions. Methods: In this prospective study, 243 conjunctival cultures were taken from 191 patients with chronic conjunctivitis, we obtained staphylococci susceptibility patterns with E-test, and they were analyzed in coagulase-positive and negative. The minimum inhibitory concentration for 90% of isolates (MIC90) was determined for Staphylococcus aureus and Staphylococcus epidermidis. Additionally, clinical follow-up and associated factors of all patients were analyzed depending on methicillin resistance (MR) or susceptibility (MS) bacterial state. Results: One hundred and eight (44%) cultures were positive; 81 positive cultures were Gram-positive of which, 77 were staphylococci, 29 coagulase-positive with S. aureus as the most prevalent, 89% MS, and 11% MR. And 48 were coagulase-negative with S. epidermidis as the most isolated with 36% of MS and 64% of MR. Poor susceptibility was found in the staphylococcus coagulase-negative/MR group. Moxifloxacin and vancomycin show the best in vitro activity for all isolates. The MIC90 of moxifloxacin and vancomycin were 0.064/1.5, 0.64/3.0, and 1/3.0 for S. aureus-MS, S. epidermidis-MS, and S. epidermidis-MR, respectively. The most frequently associated factors found in patients with positive culture for staphylococcus were exposure to the health care system 23 (29.87%) of 77 patients and dry eye 23 (29.87%) of 77 patients. Both with a proportion of 3 in 10. Conclusion: Coagulase-negative staphylococci were the most frequently isolated from the conjunctiva with 58.33% of MR; even though multiresistance was detected, their susceptibility to a fourth-generation fluoroquinolone, commonly used, such as moxifloxacin, was preserved. |
| References: | Br J Ophthalmol. 2008 Jun;92(6):848-51. (PMID: 18460536) Pol J Microbiol. 2010;59(4):233-9. (PMID: 21466040) Br J Ophthalmol. 1999 Jul;83(7):771-3. (PMID: 10381660) Ophthalmology. 2008 Jan;115(1):51-6. (PMID: 17572497) Cornea. 2002 Oct;21(7 Suppl):S86-9. (PMID: 12484705) J Cataract Refract Surg. 2010 Sep;36(9):1588-98. (PMID: 20692574) Ophthalmology. 2007 May;114(5):871-5. (PMID: 17383732) Br J Ophthalmol. 2001 Jul;85(7):842-7. (PMID: 11423460) Am J Ophthalmol. 2005 Nov;140(5):844-850. (PMID: 16310462) Invest Ophthalmol Vis Sci. 2010 Jan;51(1):362-8. (PMID: 19684005) Ophthalmology. 2005 Nov;112(11):1987. (PMID: 16183128) Arch Ophthalmol. 1997 Mar;115(3):357-61. (PMID: 9076208) Am J Ophthalmol. 2008 Nov;146(5):729-34. (PMID: 18672220) Am J Ophthalmol. 2007 Aug;144(2):313-5. (PMID: 17659970) Drug Ther Bull. 2011 Jul;49(7):78-81. (PMID: 21733975) Arq Bras Oftalmol. 2007 Jul-Aug;70(4):667-75. (PMID: 17906764) |
| المشرفين على المادة: | 0 (Anti-Bacterial Agents) 0 (Aza Compounds) 0 (Fluoroquinolones) 0 (Quinolines) 6Q205EH1VU (Vancomycin) U188XYD42P (Moxifloxacin) |
| تواريخ الأحداث: | Date Created: 20130816 Date Completed: 20140801 Latest Revision: 20231104 |
| رمز التحديث: | 20231104 |
| مُعرف محوري في PubMed: | PMC3816783 |
| DOI: | 10.1089/jop.2013.0040 |
| PMID: | 23944906 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1557-7732 |
|---|---|
| DOI: | 10.1089/jop.2013.0040 |